Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for the Treatment of Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Psychiatric Diagnosis of generalized anxiety disorder (GAD)~* Outpatients~* Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis for GAD~* Clinical Global Impression (CGI) of Severity Score of at least moderate~* Sheehan Disability Scale (SDS) Global Functioning Impairment Score \>= 12~Exclusion Criteria:~* Pregnancy or breast feeding~* Serious medical illness~* Other primary psychiatric diagnoses, such as major depressive disorder or substance abuse disorder within the past 6 months~* panic disorder, post-traumatic stress disorder (PTSD), or eating disorder in the last year~* lifetime history of bipolar or psychosis~* Any unstable serious medical condition for which duloxetine would not be allowed~* Any use of medications that are not allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).